ClinicalTrials.gg
CompletedNCT06927843Updated Sep 29, 2026

Investigational Study to Evaluate the DPP® Syphilis Screen & Confirm Antibody Point-of-care Test (POCT) to Diagnose Infectious Syphilis

An observational study in Syphilis, sponsored by University of Manitoba. Completed at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Manitoba · Observational

Updated Sep 29, 2026Now CompletedStudy completion moved+1 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
312
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the sensitivity, specificity, and utility of the DPP® Syphilis Screen \& Confirm antibody point-of-care test (POCT) to diagnose infectious syphilis in participants attending the Nine Circles Community Health Centre in Winnipeg, Manitoba.

The main questions are: Does the POCT provide accurate results compared to conventional syphilis serology methods? and Can the use of POCT improve the timeline for diagnosis and treatment of syphilis?

Researchers will compare the POCT results with conventional laboratory testing to assess if the rapid test can reliably diagnose syphilis during the initial clinic visit.

Participants will: Provide a blood sample via fingerstick for POCT testing and complete a feedback survey to evaluate the POCT experience.

Key details: This study will involve approximately 600 participants aged 18 and older over the course of 12 months which includes both new and repeat visits

02

Conditions studied

  • Syphilis

Browse trials for

Keywords

  • syphilis
  • Point of Care Test
  • Serology
03

In context

Syphilis

126 studies on the registry are indexed under Syphilis; 34 are open to participants now.

This study's enrollment of 312 is below the median of 400 across 39 observational studies indexed under Syphilis.

Browse Syphilis studies →

Lead sponsor

University of Manitoba is the lead sponsor of 555 studies on the registry; 89 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 5 (42%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population for this research comprises individuals seeking care at the Nine Circles Community Health Centre in Winnipeg, Manitoba, Canada. Participants are adults (aged 18 years or older) attending the clinic for routine sexual health care, which includes syphilis testing as part of their standard care. The clinic caters to a diverse urban population which is comprised of newcomers to Canada, indigenous, and LGBTQ2S+ community and receives a significant number of syphilis serology specimens annually, reflecting a broad spectrum of individuals who may present with varying sexual health needs. This setting provides a unique opportunity to evaluate the performance of the DPP® Syphilis Screen \& Confirm antibody point-of-care test in a real-world clinical environment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals attending the Clinic for routine sexual health care and requiring syphilis testing as part of this care
  • Be able to provide and are a minimum 18 years of age are eligible for this study
  • Those who had other STIs in the past, or being suspected of having other STIs, are not excluded as long as testing for syphilis is part of the care provided to them

Exclusion criteria

Exclusion Criteria:

  • Those who, at the discretion of the HCP/Research Nurse, appear intoxicated and/or with extreme distress, or confused, will be excluded
  • Those below the age of 18 years
  • if it has been less than 90 days since their last POCT study visit and they are asymptomatic.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
312 participants (actual)
Patient registry
No

Interventions

  • Devicepoint of care test

    DPP Syphilis Screen and Confirm antibody point-of-care-test (POCT)

06

What researchers measure

Primary outcomes

  1. Point of Care Test Performance

    Sensitivity of POCT: Percentage of participants with laboratory-confirmed active syphilis who are identified as positive by the POCT, Specificity of POCT: Percentage of participants without laboratory-confirmed active syphilis who are identified as negative by the POCT

    Time frame: From start of enrollment to the end of the enrollment period (12 months)

Secondary outcomes

  1. Secondary POCT Performance Measures

    False Positive Rate: Percentage of participants without active syphilis who test positive by POCT for active syphilis. False Negative Rate: Percentage of participants with active syphilis who test negative by POCT for active syphilis.

    Time frame: From start of enrollment to the end of the enrollment period (12 months)

  2. Comparison of Results by POCT Methodology

    Comparison of visual vs micro-reader assisted results

    Time frame: From start of enrollment to the end of the enrollment period (12 months)

07

Study locations

1 site
  • Nine Circles Community Health Centre
    Winnipeg, Manitoba R3G 0X2, Canada
08

References and documents

Individual participant data

Plan to share: No — Data and information will not be shared outside agencies for safety and privacy of the participants. Performance of POCT will be evaluated by the research team and the findings may be used for publication; however, any published or disseminated results will omit information that could potentially identify participants (name, date of birth, address and provincial health identifier number).

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Active, not recruiting→Completed
changed Sep 29, 2026
Study completion
Dec 31, 2026→Sep 28, 2026 (actual)
Sep 29, 2026
Enrollment
600 (estimated)→312 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Active, not recruiting→Completed
    Study completion Dec 31, 2026→Sep 28, 2026 (now actual)
    Enrollment 600 (estimated)→312 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06927843
Collaborators
Public Health Agency of Canada (PHAC), Chembio Diagnostic Systems, Inc.
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Mar 5, 2025
Primary completion
Mar 31, 2026
Completion
Sep 28, 2026
Last update
Sep 29, 2026

Study contacts

Principal Investigator
principal investigator · University of Manitoba

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion